Walenga J M, Fareed J
Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois.
Clin Lab Med. 1994 Dec;14(4):709-28.
Hemostasis is a balance between complex interactions of directly opposing systems (coagulation and fibrinolysis) with seemingly unrelated systems at both the enzymatic and cellular levels (platelets, endothelium, leukocytes). It should not be surprising that coagulation disorders often accompany many different disease states. Because the function of each protein involved in coagulation is now better defined, newer methodologies have been developed to assay them. In this regard, the hemostasis laboratory can take a two-step approach to diagnosis: global screening and targeted analysis. Several new global test systems provide more detailed, quantitative, and more physiologically relevant evaluations than earlier assays allowed. In addition, individual enzymes, inhibitors, cellular release products, and low molecular weight products of activation reactions (molecular markers) can now be measured in sensitive, specific assays. With this new perspective, genetic predisposition to pathologic hemostatic conditions can be identified through molecular biology and can be identified during the early stages of disease (i.e., at subclinical stages before major pathologic complications are established), and more specifically targeted prophylactic, as well as therapeutic drug interventions, can be administered. The molecular markers of hemostatic activation that can be assessed by various immunochemical methods provide very early evidence of thrombotic, fibrinolytic, or platelet-involved aberrations. Technological advances in methodology and instrumentation have changed the scope of all clinical laboratories but, in particular, that of the coagulation laboratory. The dramatic growth and development have resulted from the influences of clinical chemistry, clinical immunology, pharmacology, biochemistry, and biotechnology. Analytical instruments for use in hemostatic testing go beyond plasma or whole blood clot-based readers, platelet aggregometers, and microscopes to a range of automated, discrete, chemistrylike analyzers, spectrophotometers, microliter ELISA systems, RIA systems, and multiprobe instruments designed to measure simultaneously the different assay end-points of colorimetric and clotting assays and flow cytometers. Instruments are designed for batch processing of single tests on multiple samples or multiple test panels on a single sample. Versatility ranges from instruments that measure only the final reaction solution, by end-point or kinetic analysis, to instruments that automatically pipet reagents and sample, incubate, and analyze the reaction for truly walk-away assay performance. Typically, a wider range of assays are available in automated laboratories as opposed to laboratories performing manual assays.(ABSTRACT TRUNCATED AT 400 WORDS)
止血是直接对立系统(凝血和纤维蛋白溶解)在酶和细胞水平上与看似不相关系统(血小板、内皮细胞、白细胞)复杂相互作用之间的平衡。凝血障碍常伴随许多不同疾病状态也就不足为奇了。由于参与凝血的每种蛋白质的功能现在已得到更好的定义,因此已开发出新的方法来检测它们。在这方面,止血实验室可以采用两步法进行诊断:全面筛查和靶向分析。与早期检测相比,几种新的全面检测系统提供了更详细、定量且更具生理相关性的评估。此外,现在可以通过灵敏、特异的检测方法来测量单个酶、抑制剂、细胞释放产物以及激活反应的低分子量产物(分子标志物)。基于这种新视角,通过分子生物学可以识别病理性止血状况的遗传易感性,并且可以在疾病的早期阶段(即在主要病理并发症形成之前的亚临床阶段)识别出来,进而可以进行更具针对性的预防性以及治疗性药物干预。可通过各种免疫化学方法评估的止血激活分子标志物能提供血栓形成、纤维蛋白溶解或血小板相关异常的非常早期的证据。方法学和仪器设备的技术进步改变了所有临床实验室的范围,尤其是凝血实验室。显著的发展源于临床化学、临床免疫学、药理学、生物化学和生物技术的影响。用于止血检测的分析仪器已从基于血浆或全血凝块的读数器、血小板聚集仪和显微镜发展到一系列自动化、离散的、类似化学分析仪的仪器、分光光度计、微升酶联免疫吸附测定(ELISA)系统、放射免疫分析(RIA)系统以及旨在同时测量比色法和凝血测定不同检测终点的多探针仪器和流式细胞仪。仪器设计用于对多个样本进行单个检测的批量处理或对单个样本进行多个检测面板的处理。其通用性范围从仅通过终点或动力学分析测量最终反应溶液的仪器,到能自动吸取试剂和样本、孵育并分析反应以实现真正无需人工干预的检测性能的仪器。通常,与进行手工检测的实验室相比,自动化实验室可提供更广泛的检测项目。